FAU.de
Deutsch
Login
Home
Publications
Research Grants
Inventions & Patents
Awards
Additional Research Activities
Faculties & Institutions
Research Areas
Department of Obstetrics and Gynaecology
Friedrich-Alexander-Universität Erlangen-Nürnberg
Medizinische Fakultät
Einrichtungen, die zum Universitätsklinikum Erlangen gehören
Overview
Publications
(1,533)
Research Grants
(12)
Types of publications
Toggle all
Journal article
Journal article
Book chapter / Article in edited volumes
Book chapter / Article in edited volumes
Authored book
Authored book
Translation
Translation
Thesis
Thesis
Edited Volume
Edited Volume
Conference contribution
Conference contribution
Other publication type
Other publication type
Unpublished / Preprint
Unpublished / Preprint
Publication year
From
To
Abstract
Journal
Filters (inactive)
Progression-free survival and overall survival in patients with advanced her2-positive breast cancer treated with trastuzumab emtansine (T-dm1) after previous treatment with pertuzumab (2020)
Michel LL, Hartkopf AD, Fasching P, Kolberg HC, Hadji P, Tesch H, Häberle L, et al.
Journal article
Influence of CDK4/6 inhibitors on the peripheral immune response in hormone receptor-positive breast cancer (2020)
Peuker CA, Yaghobramzi S, Grunert C, Keilholz L, Hennig S, Schaper S, Brucker S, et al.
Conference contribution
Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system (2020)
Schmidt M, Degenhardt T, Fasching P, Lüftner D, Müller V, Thomssen C, Schem C, et al.
Journal article
Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases (2020)
Laakmann E, Witzel I, Neunhöffer T, Weide R, Schmidt M, Park-Simon TW, Möbus V, et al.
Journal article
Tissue Engineering of Lymphatic Vasculature in the Arteriovenous Loop Model of the Rat (2020)
Robering JW, Al-Abboodi M, Titzmann A, Horn I, Beier J, Horch RE, Kengelbach-Weigand A, Boos A
Journal article
Trastuzumab Biosimilars in the Therapy of Breast Cancer – “Real World” Experiences from four Bavarian University Breast Centres (2020)
Hester A, Gaß P, Fasching P, Kraemer AK, Ettl J, Diessner J, Woeckel A, et al.
Journal article
Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC) (2020)
Schneeweiss A, Moebus V, Tesch H, Klare P, Denkert C, Kast K, Hanusch C, et al.
Conference contribution
EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) plus nab-paclitaxel (nabPTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation (2020)
Sharma P, Farooki A, Fasching P, Loi S, Peterson K, Prat A, Tripathy D, et al.
Conference contribution
GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status (2020)
Link T, Blohmer JU, Just M, Untch M, Stoetzer O, Fasching P, Schneeweiss A, et al.
Conference contribution
Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332) (2020)
Hauke J, Ernst C, Fasching P, Jackisch C, Seither F, Klare P, Rhiem KE, et al.
Conference contribution
‹
1
...
63
64
65
66
67
...
154
›